Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity market.
Novo Nordisk’s Wegovy HD (semaglutide) injection 7.2 mg is available nationwide in the United States, representing the highest-dose formulation of the therapy to date.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The new product expands Novo’s portfolio as the company released
The once-weekly injectable builds on the existing Wegovy label and is positioned for adults with obesity who may require greater weight loss or who have not achieved target outcomes on lower-dose options.1
“We know that patients are looking for additional options for weight loss, and with Wegovy HD we are answering that call,” said Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk. “Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the Step Up trial, if all patients stayed on treatment, shows what's possible with this new dose.”
The
Patients receiving the 7.2 mg dose achieved average weight reductions of approximately 21% under ideal treatment conditions, compared with about 18% for the 2.4 mg dose and roughly 2% for placebo.2 When accounting for all patients regardless of treatment adherence, weight loss was approximately 19% for the higher dose versus 16% for the lower dose.2
Notably, nearly one-third of patients treated with Wegovy HD achieved at least 25% weight loss, compared with 15.3% in the 2.4 mg arm and none in the placebo group.2 Across the study, 89% of patients on the higher dose achieved at least 5% weight loss, compared with 38% for placebo.
The safety profile of the 7.2 mg dose was generally consistent with lower-dose semaglutide, with common adverse events including gastrointestinal symptoms such as nausea and vomiting, as well as fatigue, headache, and dizziness.
However, the higher dose was associated with increased rates of dysesthesia and related sensory effects, reported in 22% of patients compared with 6% for the 2.4 mg dose.1 Treatment discontinuation rates due to adverse events were similar across active treatment groups at approximately 5%.
The introduction of Wegovy HD to the U.S. market adds another layer to Novo Nordisk’s lifecycle management strategy for semaglutide, which has become a cornerstone of its growth. The company continues to expand both dosing options and access channels, with the therapy available through US pharmacies, telehealth providers, and direct distribution programs.
Wegovy HD is now available to eligible patients, with self-pay pricing starting at $199 per month for lower-dose injectable formulations and reaching approximately $399 per month for the 7.2 mg dose.1 For commercially insured patients, costs may be reduced to as little as $25 per month through existing savings programs.
The new dosage is available for patients through 70,000 pharmacies across the U.S., NovoCare Pharmacy, and select telehealth providers.1 The therapy is manufactured and packaged in the United States at Novo Nordisk’s facility in Clayton, North Carolina.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
